Rodman & Renshaw Hikes Price Target On Adventrx Pharmaceuticals (ANX) to $16
Tweet
Share
E-mailGet Alerts ANX Hot Sheet
Price: $0.73 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 3 | New: 2
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 3 | New: 2
Join SI Premium – FREE
Rodman & Renshaw raised their price target on Adventrx Pharmaceuticals (NYSE: ANX) from $4.50 to $16 while maintaining their Market Outperform rating.
Shares are on the move following the price target hike. Last trading up 9.7% to $2.60.
For more ratings news on Adventrx Pharmaceuticals click here and for the rating history of Adventrx Pharmaceuticals click here.
Shares are on the move following the price target hike. Last trading up 9.7% to $2.60.
For more ratings news on Adventrx Pharmaceuticals click here and for the rating history of Adventrx Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sea Ltd. (SE) PT Raised to $85 at Jefferies; 'Solid Execution Across Different Segments'
- Oppenheimer Reiterates Outperform Rating on Electronic Arts (EA)
- EUR/USD looks like it is consolidating before breaking to a new low: ING
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Rodman & RenshawSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
